Establish the urgency to understand that obesity is a disease that needs to be treated like other chronic, progressive diseases. Discuss the underlying physiology that leads to weight regain after weight loss with lifestyle changes alone. Review recommendations from national medical societies on the appropriate use of anti-obesity medication. Discuss data from select trials that evaluated a GLP-1 RA as a chronic weight-management therapy in patients with overweight and obesity. Review dosing and administration information and prescribing tips.
Join us for this breakfast symposium!
Interested in attending? Click here to register.
This program is developed by Novo Nordisk. This is a promotional education presentation; it will not be certified for continuing medical education credit. Presentation contains product-related education.
Novo Nordisk will report all transfers of value, including meals, as required by law. Please refrain from consuming any meals available at this event if you are a health care provider licensed in a state that prohibits, or applies limits to, such interactions. Please contact NNI Ethics & Compliance with any questions at NNIComplianceassist@NovoNordisk.com.